Short Ranbaxy, says Sudarshan Sukhani of s2analytics.com.

Do not buy Ranbaxy, says Kunal Bothra

One should not buy Ranbaxy, says Kunal Bothra, Sr Technical Analyst, LKP.

Buy Ranbaxy on dips: P Phani Sekhar

P Phani Sekhar of Angel Broking is of the view that one should buy Ranbaxy on dips.

Bull's Eye: What's hot on the charts, and what's not

Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

Super Six: Top chart picks for Friday

On CNBC-TV18's new show Super Six, market gurus Manas Jaiswal, Technical Analyst of Emkay Global, Vishal Kshatriya, Sr Derivative and Technical Analyst of Edelweiss and Nooresh Mirani, Head, AMSEC-Analyse India, place their bets on two stocks each, thus offering investors a variety of options to choose from.

Glenmark Pharma best pick in pharma space: Diwan

Glenmark Pharma is a best pick in pharma space, says Prakash Diwan, Asit C Mehta Investment.

Ranbaxy Labs a good bet, says Dilip Bhat

Ranbaxy Labs is a good bet at lower levels, says Dilip Bhat, Joint MD, Prabhudas Liladher.

Sell Ranbaxy Labs on rally: Sukhani

Sell Ranbaxy Labs on rally, says Sudarshan Sukhani of technicaltrends.com.

More downside in Ranbaxy, says Sudarshan Sukhani

More downside in Ranbaxy, says Sudarshan Sukhani, Technical Trends.

Don't buy Ranbaxy: Rakesh Bansal

Do not buy Ranbaxy, says Rakesh Bansal, CEO of rakeshbansal.com.

Exit Ranbaxy, says Somil Mehta

Somil Mehta of Sharekhan is of the view that one should exit Ranbaxy.

See more upside in Ranbaxy, says Amit Gupta

See more upside in Ranbaxy, says Amit Gupta, Head- Derivatives, ICICI Direct.

Sell Ranbaxy, says Sanjeev Agarwal

Sell Ranbaxy, says Sanjeev Agarwal, CEO of Dynamix Research & Capital Management.

Super Six stocks you can bet on Oct 5

On CNBC-TV18's in Super Six show, market gurus Hemen Kapadia, CEO of chartpundit.com, Shrikant Chouhan, VP Technical Research of Kotak Securities and Sanjeev Agarwal, CEO of Dynamix Research & Capital Management, place their bets on two stocks each, thus offering investors a variety of options to choose from.

Enter Ranbaxy around Rs 508-510: Thukral

Enter Ranbaxy Laboratories around Rs 508-510, says Hemant Thukral, Head, Derivatives Research, SBI Capital Securities.

Tulsian positive on Ranbaxy Labs

SP Tulsian of sptulsian.com is positive on Ranbaxy Labs.

Indianivesh positive on LIC Housing, Titan, Ranbaxy

Dharmesh Kant of Indianivesh Securities is positive on LIC Housing, Titan Industries and Ranbaxy, while bearish on Tata Steel.

Buy Ranbaxy, says Hemen Kapadia

Buy Ranbaxy, says Hemen Kapadia, CEO of chartpundit.com.

Super Six stocks you can bet on September 19

On CNBC-TV18's new show Super Six, market gurus Hemen Kapadia, CEO of chartpundit.com, Manas Jaiswal, Technical Analyst of Emkay Global and Sanjeev Agarwal, CEO of Dynamix Research & Capital Management, place their bets on two stocks each, thus offering investors a variety of options to choose from.

Ranbaxy Labs a good long term bet: Bhat

Ranbaxy Labs a good long term bet, says Dilip Bhat, Joint MD, Prabhudas Lilladher.

Larsen, Ranbaxy, GMR Infra may rally further: Datta

Larsen, Ranbaxy, GMR Infra may rally further, says Devangshu Datta, Consulting Editor, Outlook.

Exit Ranbaxy at Rs 520: LKP

Exit Ranbaxy at Rs 520, says Kunal Bothra, Sr Technical Analyst, LKP.

Buy Ranbaxy for target of Rs 488: LKP

Buy Ranbaxy for a target of Rs 488, says Rakesh Gandhi, Sr Technical Analyst of LKP.

Super Six intraday picks for the day

On CNBC-TV18's new show Super Six, market gurus Hemen Kapadia, CEO of chartpundit.com, Sanjeev Agarwal, CEO of Dynamix Research & Capital Management and Rakesh Gandhi, Sr Technical Analyst of LKP place their bets on two stocks each, thus offering investors a variety of options to choose from.

Buy Ranbaxy Laboratories, says Rajesh Jain

Buy Ranbaxy Laboratories, says Rajesh Jain, EVP Reatail Research, Religare Sec.